Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial

Scemblix® (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif®* (bosutinib) at 96...

Related Keywords

Georgia ,United States ,East Hanover ,Pennsylvania ,Chicago ,Illinois ,Philadelphia ,America ,American ,Jeff Legos ,Jorgee Cortes ,Sloan Simpson ,Prnewswire Novartis ,American Society Of Clinical Oncology ,Twitter ,European Hematology Association ,Novartis ,Exchange Commission ,Global Head Of Oncology Hematology Development ,Pfizer ,Approval Program ,Augusta University ,Nj Novartis Pharmaceuticals Corporation ,Georgia Cancer Center ,Novartis Pharmaceuticals Corp ,Clinical Oncology ,Executive Vice President ,Global Head ,Hematology Development ,Novartis Commitment ,Prescribing Information ,Pharmaceuticals Corporation ,Randomized Study ,Novartis Pharmaceuticals ,Allosteric Inhibitor ,Tyrosine Kinase Activity ,Chronic Myeloid Leukemia ,Reveals Significant ,Durable Responses ,Chronic Phase ,Exhibits Safety ,Phasei Study ,Asciminib Plus Nilotinib ,Therapy Using Asciminib Plus Imatinib ,Previously Treated With ,Adult Patients With Newly Diagnosed ,More Tyrosine Kinase ,Patients With ,Treatment Optimization ,Pediatric Patients With Chronic Myeloid Leukemia ,Safety Results ,Tyrosine Kinase Inhibitors ,Novartis Us ,